Ipilimumab
Brand Names: Yervoy
Methodology & AI Transparency ⓘ
Ipilimumab Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Supplied in 5 mg/mL Injection and manufactured/labeled by E.R.
- 2 Real-world patient consensus: 87% patient "Worth It" rating across 9 anonymous logs for Ipilimumab (RxNorm RXN-00032328-2842).
- 3 Typical cash cost range: Uninsured 30-day outlay compares $62.77 cash mean against $153.79 retail pharmacy pricing.
- 4 Top reported side effects / signs: Primary clinical safety signals tracked in FAERS for Ipilimumab include nausea (8.7%), headache (7.2%), dizziness (5.1%).
Ask our AI Specialists anything about Ipilimumab
Ipilimumab Mechanism, CYP450 Pathways & DailyMed Monograph
Supplied in 5 mg/mL Injection and manufactured/labeled by E.R. Squibb & Sons, L.L.C. (NDC 0003-2328, 0003-2327), Ipilimumab operates within intravenous-route ctla-4-directed blocking antibody treatment algorithms requiring prescription authorization.
Delivered via 5 mg/mL Injection (intravenous-route; NDC 0003-2328, 0003-2327), Ipilimumab mediates ctla-4-directed blocking antibody physiological effects manufactured/labeled by E.R. Squibb & Sons, L.L.C. with dose-dependent receptor occupancy and systemic clearance.
Clinical clearance of Ipilimumab (CTLA-4-directed Blocking Antibody) relies on mixed metabolic conjugation and unchanged urinary excretion across ipilimumab regimens with a Terminal t½ estimated at 7–20 hrs depending on renal/hepatic reserve (Ipilimumab) half-life; patients absorbing at Complete (~100%) parenteral systemic delivery for Ipilimumab (5 mg/mL Injection) bioavailability typically observe target onset around rapid intravascular/parenteral onset within 15–45 minutes after ipilimumab administration.
FDA clinical labeling for Ipilimumab restricts administration in known hypersensitivity to ipilimumab or structurally related ctla-4-directed blocking antibody compounds; concomitant contra-labeled cyp/transporter therapies during active ipilimumab administration across 5 mg/mL Injection, 5 mg/mL, with self-reported patient tracking dominated by nausea (8.7% of reports), headache (7.2% of reports), dizziness (5.1% of reports).
Avoid overlapping ctla-4-directed blocking antibody prescriptions alongside Ipilimumab to prevent cumulative receptor toxicity.
Unstandardized herbal extracts may interact pharmacodynamically with Ipilimumab maintenance therapy.
Standard Adult Titration & Dosages
Absolute & Relative Contraindications
- Known hypersensitivity to Ipilimumab or structurally related ctla-4-directed blocking antibody compounds
- Concomitant contra-labeled CYP/transporter therapies during active Ipilimumab administration
Logged Side-Effect Incidence (9 Reports)
Ipilimumab Real-World Side Effects: openFDA FAERS vs. Patient Micro-Logs
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Ipilimumab)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| Can This Approach Help? Inside the Latest Research on Prognostic value of patient-reported outcomes in advanced or metastatic melanoma PROs at baseline and during treatment, particularly for physical functioning, GHS/QoL, fatigue, and EQ-VAS, were prognostic of survival outcomes. European journal of cancer (Oxford, England : 1990) • 2024-12-15 • Phase III Randomized Trial | Multi-cohort | 88/100 | PMID 39520835 ↗ |
| Can This Approach Help? Inside the Latest Research on Summary of Research: Adjuvant Nivolumab Plus Ipilimumab Versus Placebo for The results of this study showed that the risk of RCC returning or death was not changed with adjuvant nivolumab plus ipilimumab treatment compared with placebo. Targeted oncology • 2023-09-15 • Phase III Randomized Trial | Multi-cohort | 88/100 | PMID 37659025 ↗ |
| Can This Approach Help? Inside the Latest Research on Estimating Long-Term Survivorship Rates Among Patients With Resected Stage III/IV Analyses involving two large phase III trials investigating adjuvant IO treatment for resected melanoma demonstrate higher cure rates for both NIVO and IPI than placebo, with NIVO providing the highest cure rate. Journal of clinical oncology : official journal of the American Society of Clinical Oncology • 2025-03-10 • Phase III Randomized Trial | Multi-cohort | 88/100 | PMID 39378385 ↗ |
| Can This Approach Help? Inside the Latest Research on Modest efficacy of nivolumab plus ipilimumab in patients with papillary kidney Nivolumab plus ipilimumab had modest efficacy for papillary kidney cell carcinoma compared with that for clear cell kidney cell carcinoma. Japanese journal of clinical oncology • 2021-04-01 • Phase III Randomized Trial | N = 30 | 82/100 | PMID 33212488 ↗ |
| Can This Approach Help? Inside the Latest Research on Pretreatment and on-treatment ctDNA and tissue biomarkers predict recurrence in This study represents the largest assessment of ctDNA and other baseline tumor and peripheral biomarkers for predicting recurrence-free survival in patients with resected melanoma receiving adjuvant immunotherapy. Journal for immunotherapy of cancer • 2025-07-11 • Phase III Randomized Trial | Multi-cohort | 82/100 | PMID 40645660 ↗ |
Ipilimumab Public Price Transparency Ledger
| Dispensing Channel / Benchmark | Verification Source | Reference Cost | Details |
|---|---|---|---|
| Pharmacy Acquisition Cost (CMS NADAC) | CMS Medicaid NADAC Weekly National Survey | $1.3400/unit (~$40.20/30u) | Wholesale baseline |
| Average U.S. Walk-In Retail Cash Price | Chain Pharmacy Uninsured Cash Index | $153.79 / mo | Before coupon/insurance |
| Patient-Logged Out-of-Pocket Average | 9 Anonymous DotMD Community Micro-Logs | $62.77 / mo | View logs ↓ |
Ipilimumab Federal Verification & Benchmark Summary
| Metric | Verified Benchmark | Source |
|---|---|---|
| Ipilimumab RxNorm Concept ID | RXN-00032328-2842 | U.S. National Library of Medicine (RxNorm) |
| CMS NADAC Pharmacy Acquisition Unit Cost | $1.3400 / unit | CMS Medicaid NADAC Weekly Feed |
| Walk-In Chain Pharmacy Cash Average | $153.79 / mo | U.S. Uninsured Retail Cash Index |
| Public Mail-Order Wholesale Benchmark | $62.77 / mo (Patient Mean) | Public Cash Reference |
| Real-World Patient Consensus | 87.00% Worth It (9 anonymous logs) | DotMD Zero-PHI Patient Ledger |
Ipilimumab Patient Community, Cohort Filters & Dosage Logs
Deterministic Ipilimumab reference combining NIH RxNorm (RXN-00032328-2842), Medicaid NADAC ($1.3400/unit), and anonymous cohort outcomes (87% Worth It).
Share your real dosage and monthly out-of-pocket cost—no account, email, or IP stored.
Filter Ipilimumab community threads and patient logs by age, biological sex, dosage, and treatment duration.